Vertex Set To Dominate Cystic Fibrosis Market For The Next Decade
Executive Summary
Vertex is set to reap huge benefits from its triple combination program for cystic fibrosis over the next 10 years, potentially becoming the biggest selling drug in this disease, according to a new report from Datamonitor Healthcare.
You may also be interested in...
Vertex Selects VX-445 For CF Triple Therapy Due To Safety/Tolerability
Already dominant in cystic fibrosis, Vertex hopes its triple regimen will address roughly 90% of the patient population. It also hopes the benefits of the triple will smooth EU reimbursement talks.
Vertex Stuck Between A Good Place And A Better Place
Two three-drug regimens for cystic fibrosis hit their primary endpoints in both heterozygous and homozygous patients, with good safety and tolerability, which analysts say increases the likelihood one of them will obtain approval.
Vertex Secures Hat Trick Of Europe CF Approvals With Nod For Symkevi
Now that the EMA has followed its US counterpart in granting approval for its cystic fibrosis drug Symkevi, Vertex will once again have to navigate Europe's various reimbursement systems, with observers keeping a close eye on how talks with NICE go.